Mereo BioPharma Group plc
Acquires and develops clinical-stage therapies for rare diseases.
MREO | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- ONE CAVENDISH PLACE, LONDON
- Website:
- https://www.mereobiopharma.com/
- Sector:
- Manufacturing
Description
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-02-11 08:00 |
Board Change
|
English | DOC • 21.5 KB | ||
| 2019-01-25 12:10 |
Publication of F-4
|
English | DOC • 37.5 KB | ||
| 2019-01-18 08:00 |
New Deferred Bonus Plan
|
English | DOC • 20.7 KB | ||
| 2019-01-15 08:00 |
BGS-649 Phase 2b data to be Presented at ENDO 2019
|
English | DOC • 25.1 KB | ||
| 2018-12-27 11:02 |
Director/PDMR Shareholding
|
English | DOC • 32.0 KB | ||
| 2018-12-24 08:00 |
Director/PDMR Shareholding
|
English | DOC • 31.9 KB | ||
| 2018-12-18 08:00 |
Positive results from safety extension study
|
English | DOC • 28.5 KB | ||
| 2018-12-17 19:25 |
Positive results from safety extension study
|
English | DOC • 27.7 KB | ||
| 2018-12-17 16:44 |
AIM Rule 17 Disclosure Statement
|
English | DOC • 21.0 KB | ||
| 2018-12-10 08:00 |
Presentation at BMO Healthcare Conference
|
English | DOC • 16.0 KB | ||
| 2018-12-05 14:09 |
Proposed combination of Mereo and OncoMed
|
English | DOC • 72.7 KB | ||
| 2018-11-26 08:00 |
Issue of Warrants
|
English | DOC • 20.5 KB | ||
| 2018-11-05 08:00 |
First patient dosed in Phase 2 study
|
English | DOC • 26.7 KB | ||
| 2018-10-31 16:37 |
Total Voting Rights
|
English | DOC • 19.2 KB | ||
| 2018-10-15 09:00 |
Completion of Patient Enrolment in Phase 2b study
|
English | DOC • 24.3 KB |
Automate Your Workflow. Get a real-time feed of all Mereo BioPharma Group plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mereo BioPharma Group plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mereo BioPharma Group plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
